Cagrilintide and retatrutide are both once-weekly subcutaneous peptides studied for weight management, but they act through entirely different hormone systems. Cagrilintide is a long-acting amylin analog, while retatrutide is a triple agonist hitting the GLP-1, GIP, and glucagon receptors. The most important thing to say up front is that both remain investigational, with no FDA-approved product for either, so the evidence behind each is still early and not on equal footing with approved drugs.
Reviewed for accuracy · Last reviewed July 8, 2026The clearest difference is mechanistic. Cagrilintide mimics amylin, a satiety hormone released alongside insulin, while retatrutide activates three incretin-related receptors at once. These are separate pathways, so the two are not variations on the same idea, and they were developed to influence appetite and metabolism in different ways.
On regulatory footing they are actually similar: both are investigational, and neither has an approved label or a defined prescribing dose. Cagrilintide has the added wrinkle that much of its later-stage evidence comes from being combined with semaglutide (as CagriSema) rather than tested alone, whereas retatrutide's published human data comes from a Phase 2 obesity trial of the single agent.
Because the two were studied in separate trials at different doses, the evidence does not support ranking one as more effective than the other, and cross-trial comparisons are unreliable. Both reported predominantly gastrointestinal side effects that eased with gradual dose escalation. Which, if either, is appropriate is a medical question, and independently sourced vials of an investigational peptide carry none of the testing a regulated product does.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.